Robert Grant, MD, MPH
Professor
Medicine
School of Medicine
Dr. Grant believes that clinical and public health practice inspires the best research. His goal is to find ways for people to breath more easily, and to end HIV transmission and disease. His work with HIV started in 1983 with the epidemic when he was a graduate student in epidemiology at UC Berkeley.
Show full bio (680 words) Hide full bio
With the completion of his work pioneering HIV pre-exposure prophylaxis (or PrEP) in 2014, he pivoted to focus on the underpinnings of the epidemic, including stigma, trauma, injustice, addiction, and depression. His current clinical practice is on pulmonary medicine, and how breathing intersects with emotional well being. The next phase of his research focuses on novel transformative interventions for depression and anxiety, including ketamine and MDMA assisted psychotherapies.
Dr. Grant has had a clinical practice in pulmonary and critical care medicine from 1994 to the present, including at Zuckerberg San Francisco General Hospital, San Francisco Veterans Administration Medical Center, and UCSF Health. He started the Sexual Health Improvement Project at UCSF in 2014; this was the first clinical service at UCSF to offer HIV preexposure prophylaxis. He served as the Chief Medical Officer of the San Francisco AIDS Foundation from 2014 to 2018, where he oversaw the initiation of the largest PrEP service in San Francisco, HIV treatment initiation in a sexual health clinic, and HCV treatment linked with a needle exchange site. The SFAF PrEP service is innovative in being rooted in a community based organization, led by nurses, pioneering same day PrEP initiation (and later, same-day HIV treatment initiation), and offering education for non-daily or 2-1-1 PrEP dosing.
Dr. Grant has served as an advisor for laboratory medicine, antiretroviral therapy, and pre-exposure prophylaxis to the CDC, the FDA, and the WHO. He helped develop the WHO recommendation for PrEP (AIDS 2016) and he drafted the WHO PrEP Implementation Tool Kit in consultation with hundreds of experts and stakeholders around the world (https://www.who.int/hiv/pub/prep/prep-implementation-tool/en/). He co-founded a ketamine assisted psychotherapy practice called "Healing Realms" in 2017, and now serves on the board of directors of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). He is a mentor in the California Institute of Integral Studies Certificate Program in Psychedelic Treatment and Research (CIIS CPTR).
Key findings from Dr. Grant's research include the following:
1. Conceptualization and estimation of transmissibility: Dr. Grant developed the concept of transmissibility (now denoted with "beta") and developed a method for estimating transmission of HIV per sexual contact and per sexual partner using epidemiological data (JID 1987). This parameter formed the basis of a generation of mathematical models of infectious epidemics.
2. Diagnostic innovations that guide therapy: Dr. Grant was the first to demonstrate that oral fluid could be used for HIV diagnostic antibody testing (CDLI 1996). He later conducted research that led to the first sequence based assay for drug resistance (or any other condition) to be approved by the FDA (J Clin Micro 2003).
3. High viral load in nonpathogenic SIV infections: Dr. Grant's laboratory discovered a null allele of CCR5 in the natural host of simian immunodeficiency virus. The host genotype was associated with viral load in nonpathogenic infection (Current Biology 1998).
4. Drug resistant HIV has diminished clinical consequences: First case report of transmission of protease inhibitor resistant HIV-1 (NEJM 1998). Finding that primary drug resistance to certain classes of antiretroviral therapy is increasing overtime, and is associated with delayed virological responses to therapy (JAMA 2002). Finding that drug resistant viremia is associated with preserved CD4+ T cell count responses to therapy, suggesting a trade-off for the virus between resistance and virulence (AIDS 1999). Persistent partial CD4+ T cell count responses proved to require continued exposure to therapy that retains partial antiviral activity and maintains selection for viruses with diminished replication capacity (NEJM 2001).
5. Pre-exposure Prophylaxis is safe, effective, and feasible: Dr. Grant's iPrEx trial found that daily oral emtricitabine/tenofovir disoproxil fumarate decreases HIV acquisition among men who have sex with men and transgender women (NEJM 2010). He also conducted the first open label demonstration project of preexposure prophylaxis, showing that adherence is higher when information about safety and efficacy is provided (Lancet ID 2014). He published the first and still largest series of PrEP use among transgender women (Deutsch 2015). He and his colleagues Identified a correlate of protection and a candidate surrogate marker for efficacy of pre-exposure prophylaxis (Anderson 2012).
Awards
Show all (8) Hide
- 150 Pioneers and Leaders in the AIDS Response, IAPAC, 2017
- Association of American Physicians, 2012
- 100 most influencial persons, Time Magazine, 2012
- Leadership Award, San Francisco AIDS Foundation, 2011
- People Who Mattered, Time Magazine, 2011
- American Society Clinical Investigation, 2003
- Alpha Omega Alpha, UCSF, 1988
- Phi Beta Kappa, Stanford, 1983
Education & Training
Show all (7) Hide
- Certificate Psychedelic Treatment and Research California Institute of Integral Studies 2016
- Fellowship Pulmonary Medicine University of California, San Francisco 1996
- Residency School of Medicine University of California, San Francisco 1991
- M.D. Medicine University of California, San Francisco 1988
- M.P.H Epidemiology University of California, Berkeley 1986
- M.H.S. Health and Medical Sciences University of California, Berkeley 1986
- B.S., A.B Biology, Latin American Studies Stanford University 1983
Interests
Show all (6) Hide
- HIV
- MDMA for PTSD treatment
- Psychotherapy with Internal Family Systems
- Epidemic Modeling
- Ketamine therapy for mental health
- Evolution and Drug Resistance
Grants and Projects
Show all (9) Hide
- Ketamine therapy for Palliative Care, Osher Center, 2020-2021
- Chemoprophylaxis and HIV Host Interactions, NIH, 2015-2021
- Support of Yerkes National Primate Research Center, NIH, 1976-2016
- The Biology of HIV Transmission, NIH, 2007-2014
- Chemoprophylaxis and HIV-Host Interactions, NIH, 2004-2013
- Chemoprophylaxis for HIV Prevention in Men, NIH, 2004-2013
- Mechanisms Blocking HIV-1 Superinfection, NIH, 2003-2008
- Gender Effects on Hiv Biology, NIH, 2001-2008
- General Clinical Research Center, NIH, 1974-2007
Publications (178)
Top publication keywords:
Transgender PersonsDeoxycytidineHomosexuality, MaleMedication AdherenceDrug Resistance, ViralSexual BehaviorAnti-HIV AgentsPre-Exposure ProphylaxisTenofovirEmtricitabineOrganophosphonatesChemopreventionHIV-1AdenineHIV Infections
-
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, … -
HIV moments and pre-exposure prophylaxis.
Lancet (London, England) 2016 Grant RM, Glidden DV -
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
The lancet. HIV 2015 Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators -
Ending sexual HIV transmission: lessons learned from perinatal HIV.
The Journal of the Association of Nurses in AIDS Care : JANAC 2015 Weber S, Grant RM -
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.
The Lancet. Infectious diseases 2014 Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira… -
Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men.
PloS one 2010 McConnell JJ, Bragg L, Shiboski S, Grant RM -
Research in situ.
Nature methods 2007 Grant RM -
Time trends in primary HIV-1 drug resistance among recently infected persons.
JAMA 2002 Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO
Show all (170 more) Hide
-
HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, … -
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Garcia-Cremades M, Vucicevic K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM -
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.
Pharmaceutics 2022 Garcia-Cremades M, Hendrix CW, Jayachandran P, Strydom N, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM -
Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California.
Journal of acquired immune deficiency syndromes (1999) 2021 Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, Venegas L, Grant RM -
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB -
Human Enough: A Qualitative Study of Client Experience With Internet-Based Access to Pre-exposure Prophylaxis.
Journal of medical Internet research 2021 Hughes SD, Koester KA, Engesaeth E, Hawkins MV, Grant RM -
Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis.
AIDS research and human retroviruses 2021 Ibrahim ME, Glidden DV, Grant RM, Anderson PL -
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M -
Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx Participants.
Journal of acquired immune deficiency syndromes (1999) 2021 Truong HM, Mehrotra ML, Grant RM, iPrEx Study Team -
Non-B variants of HIV-1 in San Francisco, California.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2020 O'Keefe KJ, Pipkin S, Fatch R, Scheer S, Liegler T, McFarland W, Grant RM, Truong HM -
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet (London, England) 2020 Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, … -
Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC -
The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT.
AIDS and behavior 2020 Velloza J, Heffron R, Amico KR, Rowhani-Rahbar A, Hughes JP, Li M, Dye BJ, Celum C, Bekker LG, Grant RM, HPTN 067/ADAPT Study Team -
Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
Journal of acquired immune deficiency syndromes (1999) 2020 Spinelli MA, Rodrigues WC, Wang G, Vincent M, Glidden DV, Okochi H, Stalter R, Defechereux P, Deutsch M, Grant RM, Ngure K, Mugo NR, Baeten JM, Gandhi M, Partners PrEP Study Team -
HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
AIDS (London, England) 2020 Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, Mehrotra ML, Defechereux P, Gandhi M, Grant RM, Shlipak MG, Jotwani V -
Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!
Journal of the American Pharmacists Association : JAPhA 2020 Lopez MI, Grant RM, Dong BJ -
"A Good Habit": Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements.
Journal of the International Association of Providers of AIDS Care 2020 Koester KA, Hughes SD, Grant RM -
Response to: Acceptability and Feasibility of a Pharmacist-Led HIV Pre-exposure Prophylaxis Program in the Midwestern United States.
Open forum infectious diseases 2019 Dong BJ, Lopez MI, Grant RM -
HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013.
Journal of acquired immune deficiency syndromes (1999) 2019 Holtz TH, Chitwarakorn A, Hughes JP, Curlin ME, Varangrat A, Li M, Amico KR, Mock PA, Grant RM, Thai HPTN 067/ADAPT Study Team -
Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
Journal of acquired immune deficiency syndromes (1999) 2019 Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin ME, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM, HPTN 067/… -
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Journal of acquired immune deficiency syndromes (1999) 2019 Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW -
Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California.
Journal of acquired immune deficiency syndromes (1999) 2019 Myers JJ, Kang Dufour MS, Koester KA, Udoh I, Frazier R, Packard R, Kennedy K, Erguera X, Horowitz J, Grant R, Burack JH -
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Journal of acquired immune deficiency syndromes (1999) 2019 Mehrotra ML, Westreich D, McMahan VM, Glymour MM, Geng E, Grant RM, Glidden DV -
Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
AIDS research and human retroviruses 2019 Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM -
Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study.
AIDS care 2019 Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, Holtz TH, HPTN 067/ADAPT Study Team -
Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function.
Journal of acquired immune deficiency syndromes (1999) 2019 Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW -
Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067.
Journal of acquired immune deficiency syndromes (1999) 2019 Mannheimer S, Hirsch-Moverman Y, Franks J, Loquere A, Hughes JP, Li M, Amico KR, Grant RM -
Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.
AIDS (London, England) 2019 Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M -
Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015.
PloS one 2019 Truong HM, Pipkin S, Grant RM, Liegler T, O'Keefe KJ, Scheer S -
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
The lancet. HIV 2018 Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M -
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
HIV clinical trials 2018 Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA -
The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men.
AIDS and behavior 2018 Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM -
Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis.
Open forum infectious diseases 2018 Stekler JD, Violette LR, Niemann L, McMahan VM, Katz DA, Baeten JM, Grant RM, Delaney KP -
"Losing the Phobia:" Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men.
Frontiers in public health 2018 Koester KA, Erguera XA, Kang Dufour MS, Udoh I, Burack JH, Grant RM, Myers JJ -
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, Ananworanich J, Robb ML, Phanuphak N -
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM -
Characterization of HIV Recent Infection Among High-Risk Men at Public STI Clinics in Mumbai.
AIDS and behavior 2018 Truong HM, Fatch R, Grant RM, Mathur M, Kumta S, Jerajani H, Kellogg TA, Lindan CP -
Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Journal of acquired immune deficiency syndromes (1999) 2018 Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG -
Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study.
Frontiers in public health 2018 Ryan KE, Mak A, Stoove M, Price B, Fairley CK, Ruth S, Lal L, Asselin J, El-Hayek C, Nguyen L, Batrouney C, Wilson D, Lockwood J, Murphy D, Cornelisse VJ, Roth N, Willcox J, Chang CC, Armishaw J, Tee … -
The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Journal of psychopharmacology (Oxford, England) 2018 Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E -
Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
PloS one 2018 Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN -
Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study.
AIDS and behavior 2018 Franks J, Hirsch-Moverman Y, Loquere AS, Amico KR, Grant RM, Dye BJ, Rivera Y, Gamboa R, Mannheimer SB -
In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?
AIDS (London, England) 2018 Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC -
A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis.
AIDS patient care and STDs 2018 Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY -
Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.
Journal of the International AIDS Society 2018 Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW -
Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2018 Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM -
Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.
PloS one 2018 Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY -
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
Journal of acquired immune deficiency syndromes (1999) 2017 Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H -
HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.
AIDS care 2017 Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM -
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
The lancet. HIV 2017 Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant … -
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Journal of acquired immune deficiency syndromes (1999) 2017 Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM -
Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.
AIDS (London, England) 2017 Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E, VicPrEP Study Team -
Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
Journal of acquired immune deficiency syndromes (1999) 2017 Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH, … -
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
The lancet. HIV 2017 Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR… -
Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures?
American journal of obstetrics and gynecology 2017 Seidman DL, Weber S, Grant RM -
Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
AIDS and behavior 2017 Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM -
International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status.
Sexually transmitted diseases 2017 Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM -
Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.
AIDS and behavior 2017 Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, Rodolph M, Hodges-Mameletzis I, Kennedy CE -
Risk, safety and sex among male PrEP users: time for a new understanding.
Culture, health & sexuality 2017 Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, Hosek S, Grant R -
Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum?
Sexually transmitted infections 2017 Glidden DV, Mayer K, Grant RM -
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.
AIDS research and human retroviruses 2017 Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, … -
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices.
Journal of the International AIDS Society 2016 Sevelius JM, Deutsch MB, Grant R -
Pharmacology supports on-demand PrEP.
The lancet. HIV 2016 Glidden DV, Anderson PL, Grant RM -
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
The lancet. HIV 2016 Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM -
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis.
Journal of acquired immune deficiency syndromes (1999) 2016 Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB -
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
AIDS (London, England) 2016 Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM -
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
AIDS and behavior 2016 Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM, iPrEx Study Team -
HIV Serodisclosure and Sexual Behavior During International Travel.
Sexually transmitted diseases 2016 Truong HM, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT -
The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.
AIDS and behavior 2016 Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM -
Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.
Journal of acquired immune deficiency syndromes (1999) 2016 Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF -
PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply.
The lancet. HIV 2016 Sevelius J, Deutsch MB, Glidden DV, Grant RM -
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Journal of acquired immune deficiency syndromes (1999) 2016 Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant RM, Mugwanya KK, Baeten JM, Wyatt CM -
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Journal of acquired immune deficiency syndromes (1999) 2016 Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM, iPrEx Study Team -
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM -
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
JAMA internal medicine 2016 Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, … -
What people want from sex and preexposure prophylaxis.
Current opinion in HIV and AIDS 2016 Grant RM, Koester KA -
Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Koester KA, Grant RM -
Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment.
Open forum infectious diseases 2015 Grant RM, Smith DK -
Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.
The Journal of infectious diseases 2015 Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF -
Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco.
Journal of acquired immune deficiency syndromes (1999) 2015 Truong HM, Pipkin S, O'Keefe KJ, Louie B, Liegler T, McFarland W, Grant RM, Bernstein K, Scheer S -
Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.
Proceedings of the National Academy of Sciences of the United States of America 2015 Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, … -
The FACTS about women and pre-exposure prophylaxis.
The lancet. HIV 2015 Seidman D, Weber S, Aaron E, Cohan D, Grant R -
Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
AIDS care 2015 Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, Hosek S, Mayer KH, Grant RM -
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG… -
Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
The Journal of infectious diseases 2015 Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM, iPrEx Study Team -
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
AIDS (London, England) 2015 Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV -
Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.
The Journal of infectious diseases 2015 Grant RM, Liegler T -
Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag.
Bio-protocol 2014 Gesner M, Maiti M, Grant R, Cavrois M -
Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial.
International journal of STD & AIDS 2014 Solomon MM, Nureña CR, Tanur JM, Montoya O, Grant RM, McConnell JJ -
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.
Journal of acquired immune deficiency syndromes (1999) 2014 Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant… -
Streamlining HIV testing for HIV preexposure prophylaxis.
Journal of clinical microbiology 2014 Guanira JV, Leigler T, Kallas E, Schechter M, Sharma U, Glidden D, Grant RM, iPrEx Study Team -
Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco.
Sexually transmitted infections 2014 Truong HM, Fatch R, Grasso M, Robertson T, Tao L, Chen YH, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT -
Reply to Boyd et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Solomon MM, Mayer KH, Glidden DV, Guanira JV, Grant RM -
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.
Journal of acquired immune deficiency syndromes (1999) 2014 Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R -
HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.
JAMA 2014 Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA, … -
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM, iPrEx Study Team -
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
The Journal of infectious diseases 2014 Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM, iPrEx Study Team -
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
AIDS (London, England) 2014 Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, Guanira JV, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Burns DN, Grant RM, iPrEx Study Team -
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
PloS one 2014 Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant RM -
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
The Lancet. Infectious diseases 2014 Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM -
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
PloS one 2014 Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M -
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
PloS one 2013 Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM -
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Journal of acquired immune deficiency syndromes (1999) 2013 Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O'hara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP -
Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men.
PloS one 2013 Vallabhaneni S, McConnell JJ, Loeb L, Hartogensis W, Hecht FM, Grant RM, Pilcher CD -
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
PLoS medicine 2012 Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB -
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Science translational medicine 2012 Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant … -
Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.
AIDS and behavior 2012 R Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, Liu A -
Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection.
PloS one 2011 Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant RM -
Differential persistence of transmitted HIV-1 drug resistance mutation classes.
The Journal of infectious diseases 2011 Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM -
Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.
PloS one 2010 Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM -
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
The Journal of antimicrobial chemotherapy 2010 Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM -
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
The New England journal of medicine 2010 Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S… -
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Grant RM -
HIV RNA level in early infection is predicted by viral load in the transmission source.
AIDS (London, England) 2010 Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG -
Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance.
Journal of travel medicine 2008 Truong HM, Kellogg T, Schwarcz S, Delgado V, Grant RM, Louie B, Ngo H, McFarland W -
Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus.
PLoS pathogens 2008 Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, Hecht FM, Grant RM, Nixon DF -
Whither or wither microbicides?
Science (New York, N.Y.) 2008 Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA -
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.
PLoS pathogens 2007 Bourara K, Liegler TJ, Grant RM -
Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study.
AIDS research and human retroviruses 2007 Abrams DI, Shade SB, Couey P, McCune JM, Lo J, Bacchetti P, Chang B, Epling L, Liegler T, Grant RM -
Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.
The Journal of biological chemistry 2006 Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC -
Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance.
AIDS (London, England) 2006 Truong HM, Grant RM, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD -
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.
AIDS (London, England) 2006 Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM -
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo.
Journal of virology 2006 Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V -
Chemoprophylaxis of HIV infection: moving forward with caution.
The Journal of infectious diseases 2006 Grant RM, Wainberg MA -
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006 Levy V, Grant RM -
Preexposure prophylaxis for HIV: unproven promise and potential pitfalls.
JAMA 2006 Liu AY, Grant RM, Buchbinder SP -
Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance.
Journal of acquired immune deficiency syndromes (1999) 2006 Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, Whittington WL, Celum C, Grant RM, Peruvian HIV Sentinel Surveillance Working Group -
HIV drug-resistant strains as epidemiologic sentinels.
Emerging infectious diseases 2006 Sánchez MS, Grant RM, Porco TC, Getz WM -
Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.
Journal of acquired immune deficiency syndromes (1999) 2006 Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R -
High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2005 Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN -
Seroconversion following nonoccupational postexposure prophylaxis against HIV.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN -
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Science (New York, N.Y.) 2005 Grant RM, Buchbinder S, Cates W, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg … -
Resistance testing in drug-naive HIV-infected patients: is it time?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Hecht FM, Grant RM -
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
The Journal of infectious diseases 2005 Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN -
Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy.
AIDS (London, England) 2005 Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM -
Detection of acute HIV infections.
The New England journal of medicine 2005 Klausner JD, Grant RM, Kent CK -
T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2005 Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant RM, Price RW -
The role of viral fitness in HIV pathogenesis.
Current HIV/AIDS reports 2005 Barbour JD, Grant RM -
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.
PLoS medicine 2004 Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ -
A decrease in drug resistance levels of the HIV epidemic can be bad news.
Bulletin of mathematical biology 2004 Sánchez MS, Grant RM, Porco TC, Gross KL, Getz WM -
HIV-producing T cells in cerebrospinal fluid.
Journal of acquired immune deficiency syndromes (1999) 2004 Neuenburg JK, Sinclair E, Nilsson A, Kreis C, Bacchetti P, Price RW, Grant RM -
Persistence of primary drug resistance among recently HIV-1 infected adults.
AIDS (London, England) 2004 Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM -
HIV-1 superinfection and viral diversity.
AIDS (London, England) 2004 Gross KL, Porco TC, Grant RM -
Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
Journal of virology 2004 Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC -
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
The Journal of infectious diseases 2004 Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM -
The Clinical Implications of Reduced Viral Fitness.
Current infectious disease reports 2004 Barbour JD, Grant RM -
Relating HIV-1 sequence variation to replication capacity via trees and forests.
Statistical applications in genetics and molecular biology 2004 Segal MR, Barbour JD, Grant RM -
Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection.
AIDS (London, England) 2004 Angel JB, Hu YW, Kravcik S, Tsui R, Lee KH, Barbour J, Balaskas E, Branson BM, Delwart EL, Grant RM -
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy.
AIDS (London, England) 2004 Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH -
Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.
Journal of virology 2004 Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL -
Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.
AIDS (London, England) 2003 Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ -
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
AIDS (London, England) 2003 Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A -
Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients.
Journal of acquired immune deficiency syndromes (1999) 2003 Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP -
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
Journal of virology 2003 Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF -
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003 D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD -
Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection.
Transfusion 2003 Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CM, Grant RM, Busch MP, Viral Activation Transfusion Study Group -
Accuracy of the TRUGENE HIV-1 genotyping kit.
Journal of clinical microbiology 2003 Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Reid C, Morgan GF, Winslow DL -
Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.
Journal of clinical microbiology 2003 Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Reid C, Morgan GF, Winslow DL -
Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays.
AIDS (London, England) 2003 Hayden MS, Palacios EH, Grant RM -
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.
AIDS (London, England) 2003 Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ -
Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.
AIDS (London, England) 2002 Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF -
Drug Resistance Mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2002 D'Aquila RT, International AIDS Society-USA , Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD -
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection.
Journal of virology 2002 Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant RM, Bhardwaj N, Rosenberg MG, Nixon DF -
Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.
AIDS (London, England) 2002 Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM -
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.
The Journal of experimental medicine 2002 Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA -
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
AIDS (London, England) 2002 Deeks SG, Barbour JD, Grant RM, Martin JN -
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.
The Journal of infectious diseases 2002 Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK -
Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection.
Journal of hepatology 1999 Hassoba HM, Bzowej N, Berenguer M, Kim M, Zhou S, Phung Y, Grant R, Pessoa MG, Wright TL -
Cloning and characterization of the RNA polymerase alpha-subunit operon of Chlamydia trachomatis.
Journal of bacteriology 1993 Tan M, Klein R, Grant R, Ganem D, Engel J -
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study.
JAMA 1987 Winkelstein W, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA